Robert J. Kreitman, MD, of the National Cancer Institute, discusses findings on moxetumomab pasudotox in heavily pretreated patients with relapsed or refractory hairy cell leukemia (Abstract 7004).
Kathleen N. Moore, MD, of the University of Oklahoma Health Sciences Center, discusses phase II study findings on niraparib in patients with relapsed ovarian cancer who have received three or more prior chemotherapy regimens (Abstract 5514).
Sibylle Loibl, MD, PhD, of the German Breast Group, discusses phase II study findings on the addition of durvalumab to a taxane-anthracycline–containing chemotherapy in triple-negative breast cancer (Abstract 104).
Emily S. Ruiz, MD, MPH, of Brigham and Women’s Cancer Center, discusses new developments in the treatment of squamous cell skin cancer and what she sees on the therapeutic horizon (Abstracts e18703, 9519, and 9577).
Thaddeus Mason Pope, JD, PhD, of the Mitchell Hamline School of Law, discusses implications of the federal “Right to Try” law, recently enacted.
Gilberto Lopes, MD, MBA, of the Sylvester Comprehensive Cancer Center at the University of Miami, discusses phase III findings on pembrolizumab vs platinum-based chemotherapy as first-line treatment for advanced/metastatic non–small cell lung cancer with a PD-L1 tumor proportion score ≥ to 1% (Abstract LBA4).
